Search

Your search keyword '"Gossec, L"' showing total 1,441 results
Start Over Author "Gossec, L"
1,441 results on '"Gossec, L"'

51. AB1148 PATIENT AND PHYSICIAN GLOBAL ASSESSMENT OF PSORIATIC ARTHRITIS APPEAR MORE IN AGREEMENT IN ARAB COUNTRIES THAN PREVIOUSLY REPORTED ELSEWHERE – AN INTERNATIONAL STUDY UNDER THE AEGIS OF ARLAR

Author

Ziade, N., primary, Abbas, N., additional, Kibbi, L., additional, Maroof, A., additional, Zorkany, B., additional, Al-Ani, N. A., additional, Ridha, A., additional, Ihsan, N., additional, Isho Gorial, F., additional, Al Chama, N., additional, Haouichet, C., additional, Alnaimat, F., additional, Hannawi, S., additional, Atawina, S., additional, Halabi, H., additional, Mashaleh, M., additional, Aljazwi, L., additional, Abogamal, A., additional, Ayoub, L., additional, Bouajina, E., additional, Bahiri, R., additional, Saad, S., additional, Sabkar, M., additional, Aouad, K., additional, Gossec, L., additional, and Hmamouchi, I., additional

Published
2023
Full Text
View/download PDF

52. Gender-specific differences in patients with psoriatic arthritis receiving ustekinumab or tumour necrosis factor inhibitor: real-world data.

Author

Kuijk, A.W.R. van, Nurmohamed, M.T., Siebert, S., Bergmans, P., Vlam, K. de, Gremese, E., Joven-Ibáñez, B., Korotaeva, T.V., Lavie, F., Sharaf, M., Noël, W., Theander, E., Smolen, J.S., Gossec, L., Horst-Bruinsma, I.E. van der, Kuijk, A.W.R. van, Nurmohamed, M.T., Siebert, S., Bergmans, P., Vlam, K. de, Gremese, E., Joven-Ibáñez, B., Korotaeva, T.V., Lavie, F., Sharaf, M., Noël, W., Theander, E., Smolen, J.S., Gossec, L., and Horst-Bruinsma, I.E. van der

Abstract

Item does not contain fulltext, OBJECTIVE: Investigate effects of gender on disease characteristics and treatment impact in patients with PsA. METHODS: PsABio is a non-interventional European study in patients with PsA starting a biological DMARD [bDMARD; ustekinumab or TNF inhibitor (TNFi)]. This post-hoc analysis compared persistence, disease activity, patient-reported outcomes and safety between male and female patients at baseline and 6 and 12 months of treatment. RESULTS: At baseline, disease duration was 6.7 and 6.9 years for 512 females and 417 males respectively. Mean (95% CI) scores for females vs males were: clinical Disease Activity Index for Psoriatic Arthritis (cDAPSA), 32.3 (30.3, 34.2) vs 26.8 (24.8, 28.9); HAQ-Disability Index (HAQ-DI), 1.3 (1.2, 1.4) vs 0.93 (0.86, 0.99); total PsA Impact of Disease-12 (PsAID-12) score, 6.0 (5.8, 6.2) vs 5.1 (4.9, 5.3), respectively. Improvements in scores were smaller in female than male patients. At 12 months, 175/303 (57.8%) female and 212/264 (80.3%) male patients achieved cDAPSA low disease activity, 96/285 (33.7%) and 137/247 (55.5%), achieved minimal disease activity (MDA), respectively. HAQ-DI scores were 0.85 (0.77, 0.92) vs 0.50 (0.43, 0.56), PsAID-12 scores 3.5 (3.3, 3.8) vs 2.4 (2.2, 2.6), respectively. Treatment persistence was lower in females than males (P ≤ 0.001). Lack of effectiveness was the predominant reason to stop, irrespective of gender and bDMARD. CONCLUSIONS: Before starting bDMARDs, females had more severe disease than males and a lower percentage reached favourable disease states, with lower persistence of treatment after 12 months. A better understanding of the mechanisms underlying these differences may improve therapeutic management in females with PsA. TRIAL REGISTRATION: ClinicalTrials.gov, https://clinicaltrials.gov, NCT02627768.

Published
2023

54. Pratiques et croyances alimentaires des patients atteints de maladies rhumatismales et relation avec les symptômes : résultats d’une étude transversale multicentrique

Author

Renard, D., primary, Tuffet, S., additional, Dieudé, P., additional, Claudepierre, P., additional, Gossec, L., additional, Fautrel, B., additional, Molto, A., additional, Richard, C. Miceli, additional, Richette, P., additional, Maheu, E., additional, Carette, C., additional, Czernichow, S., additional, Jamakorzyan, C., additional, Rousseau, A., additional, Berenbaum, F., additional, Beauvais, C., additional, and Sellam, J., additional

Published
2022
Full Text
View/download PDF

55. Le bimékizumab réduit fatigue et douleur chez les patients atteints de rhumatisme psoriasique actif, naïfs de biologiques ou avec réponse inadéquate (RI) aux anti-TNF : résultats à 16 semaines de 2 études de phase III randomisées, contrôlées par placebo

Author

Gossec, L., primary, Husni, M.E., additional, Mease, P.J., additional, Merola, J.F., additional, Behrens, F., additional, Favalli, E.G., additional, McGonagle, D., additional, Tillett, W., additional, Tsuji, S., additional, Ink, B., additional, Assudani, D., additional, Bajracharya, R., additional, Coarse, J., additional, and Lambert, J., additional

Published
2022
Full Text
View/download PDF

56. Le bimékizumab améliore la qualité de vie chez les patients atteints de rhumatisme psoriasique actif, naïfs de biologiques ou avec réponse inadéquate aux anti-TNF : résultats à 16 semaines de 2 études de phase III randomisées, contrôlées par placebo

Author

Gossec, L., primary, Gladman, D.D., additional, Kristensen, L.E., additional, Thaçi, D., additional, Gisondi, P., additional, Husni, M.E., additional, Gottlieb, A.B., additional, Dobashi, H., additional, Ink, B., additional, Assudani, D., additional, Bajracharya, R., additional, Coarse, J., additional, Lambert, J., additional, and Tillett, W., additional

Published
2022
Full Text
View/download PDF

57. Le bimékizumab chez des patients atteints de rhumatisme psoriasique et naïfs de biologique : évaluation de l’efficacité et de la tolérance à 24 semaines dans une étude de phase III

Author

Gossec, L., primary, McInnes, I.B., additional, Coates, L.C., additional, Landewé, R.B., additional, Mease, P.J., additional, Ritchlin, C.T., additional, Tanaka, Y., additional, Asahina, A., additional, Gottlieb, A.B., additional, Warren, R.B., additional, Ink, B., additional, Assudani, D., additional, Coarse, J., additional, Bajracharya, R., additional, and Merola, J.F., additional

Published
2022
Full Text
View/download PDF

58. Le bimékizumab chez des patients atteints de rhumatisme psoriasique et présentant une réponse inadéquate aux anti-TNF : évaluation de l’efficacité et de la tolérance à 16 semaines dans une étude de phase III

Author

Gossec, L., primary, Merola, J.F., additional, McInnes, I.B., additional, Ritchlin, C.T., additional, Mease, P.J., additional, Landewé, R.B., additional, Asahina, A., additional, Tanaka, Y., additional, Warren, R.B., additional, Gladman, D.D., additional, Behrens, F., additional, Ink, B., additional, Assudani, D., additional, Bajracharya, R., additional, Coarse, J., additional, and Coates, L.C., additional

Published
2022
Full Text
View/download PDF

61. SARS-CoV-2 outbreak in immune-mediated inflammatory diseases: the Euro-COVIMID multicentre cross-sectional study

Author

Saadoun, D, Vieira, M, Vautier, M, Baraliakos, X, Andreica, I, da Silva, J, Sousa, M, Luis, M, Khmelinskii, N, Gracia, J, Castrejon, I, Gonzalez, J, Scire, C, Silvagni, E, Bortoluzzi, A, Penn, H, Hamdulay, S, Machado, P, Fautrel, B, Cacoub, P, Resche-Rigon, M, Gossec, L, Saadoun D., Vieira M., Vautier M., Baraliakos X., Andreica I., da Silva J. A. P., Sousa M., Luis M., Khmelinskii N., Gracia J. M. A., Castrejon I., Gonzalez J. C. N., Scire C. A., Silvagni E., Bortoluzzi A., Penn H., Hamdulay S., Machado P. M., Fautrel B., Cacoub P., Resche-Rigon M., Gossec L., Saadoun, D, Vieira, M, Vautier, M, Baraliakos, X, Andreica, I, da Silva, J, Sousa, M, Luis, M, Khmelinskii, N, Gracia, J, Castrejon, I, Gonzalez, J, Scire, C, Silvagni, E, Bortoluzzi, A, Penn, H, Hamdulay, S, Machado, P, Fautrel, B, Cacoub, P, Resche-Rigon, M, Gossec, L, Saadoun D., Vieira M., Vautier M., Baraliakos X., Andreica I., da Silva J. A. P., Sousa M., Luis M., Khmelinskii N., Gracia J. M. A., Castrejon I., Gonzalez J. C. N., Scire C. A., Silvagni E., Bortoluzzi A., Penn H., Hamdulay S., Machado P. M., Fautrel B., Cacoub P., Resche-Rigon M., and Gossec L.

Abstract

Background: The COVID-19 pandemic has raised numerous questions among patients with immune-mediated inflammatory diseases regarding potential reciprocal effects of COVID-19 and their underlying disease, and potential effects of immunomodulatory therapy on outcomes related to COVID-19. The seroprevalence of SARS-CoV-2 and factors associated with symptomatic COVID-19 in patients with immune-mediated inflammatory diseases are still unclear. The Euro-COVIMID study aimed to determine the serological and clinical prevalence of COVID-19 among patients with immune-mediated inflammatory diseases, as well as factors associated with COVID-19 occurrence and the impact of the pandemic in its management. Methods: In this multicentre cross-sectional study, patients aged 18 years or older with a clinical diagnosis of rheumatoid arthritis, axial spondyloarthritis, systemic lupus erythematosus, Sjögren's syndrome, or giant cell arteritis were recruited from six tertiary referral centres in France, Germany, Italy, Portugal, Spain, and the UK. Demographics, comorbidities, treatments, and recent disease flares, as well as information on COVID-19 symptoms, were collected through a questionnaire completed by participants. SARS-CoV-2 serology was systematically tested. The main outcome was the serological and clinical prevalence of COVID-19. Factors associated with symptomatic COVID-19 were assessed by multivariable logistic regression, and incidence of recent disease flares, changes in treatments for underlying disease, and the reasons for treatment changes were also assessed. This study is registered with ClinicalTrials.gov, NCT04397237. Findings: Between June 7 and Dec 8, 2020, 3136 patients with an immune-mediated inflammatory disease answered the questionnaire. 3028 patients (median age 58 years [IQR 46–67]; 2239 [73·9%] women and 789 [26·1%] men) with symptomatic COVID-19, serological data, or both were included in analyses. SARS-CoV-2 antibodies were detected in 166 (5·5% [95% CI 4·

Published
2021

62. Factors associated with COVID-19-related death in people with rheumatic diseases: Results from the COVID-19 Global Rheumatology Alliance physician-reported registry

Author

Strangfeld, A, Schafer, M, Gianfrancesco, M, Lawson-Tovey, S, Liew, J, Ljung, L, Mateus, E, Richez, C, Santos, M, Schmajuk, G, Scire, C, Sirotich, E, Sparks, J, Sufka, P, Thomas, T, Trupin, L, Wallace, Z, Al-Adely, S, Bachiller-Corral, J, Bhana, S, Cacoub, P, Carmona, L, Costello, R, Costello, W, Gossec, L, Grainger, R, Hachulla, E, Hasseli, R, Hausmann, J, Hyrich, K, Izadi, Z, Jacobsohn, L, Katz, P, Kearsley-Fleet, L, Robinson, P, Yazdany, J, Machado, P, Strangfeld A., Schafer M., Gianfrancesco M. A., Lawson-Tovey S., Liew J. W., Ljung L., Mateus E. F., Richez C., Santos M. J., Schmajuk G., Scire C. A., Sirotich E., Sparks J. A., Sufka P., Thomas T., Trupin L., Wallace Z. S., Al-Adely S., Bachiller-Corral J., Bhana S., Cacoub P., Carmona L., Costello R., Costello W., Gossec L., Grainger R., Hachulla E., Hasseli R., Hausmann J. S., Hyrich K. L., Izadi Z., Jacobsohn L., Katz P., Kearsley-Fleet L., Robinson P. C., Yazdany J., Machado P. M., Strangfeld, A, Schafer, M, Gianfrancesco, M, Lawson-Tovey, S, Liew, J, Ljung, L, Mateus, E, Richez, C, Santos, M, Schmajuk, G, Scire, C, Sirotich, E, Sparks, J, Sufka, P, Thomas, T, Trupin, L, Wallace, Z, Al-Adely, S, Bachiller-Corral, J, Bhana, S, Cacoub, P, Carmona, L, Costello, R, Costello, W, Gossec, L, Grainger, R, Hachulla, E, Hasseli, R, Hausmann, J, Hyrich, K, Izadi, Z, Jacobsohn, L, Katz, P, Kearsley-Fleet, L, Robinson, P, Yazdany, J, Machado, P, Strangfeld A., Schafer M., Gianfrancesco M. A., Lawson-Tovey S., Liew J. W., Ljung L., Mateus E. F., Richez C., Santos M. J., Schmajuk G., Scire C. A., Sirotich E., Sparks J. A., Sufka P., Thomas T., Trupin L., Wallace Z. S., Al-Adely S., Bachiller-Corral J., Bhana S., Cacoub P., Carmona L., Costello R., Costello W., Gossec L., Grainger R., Hachulla E., Hasseli R., Hausmann J. S., Hyrich K. L., Izadi Z., Jacobsohn L., Katz P., Kearsley-Fleet L., Robinson P. C., Yazdany J., and Machado P. M.

Abstract

Objectives To determine factors associated with COVID-19-related death in people with rheumatic diseases. Methods Physician-reported registry of adults with rheumatic disease and confirmed or presumptive COVID-19 (from 24 March to 1 July 2020). The primary outcome was COVID-19-related death. Age, sex, smoking status, comorbidities, rheumatic disease diagnosis, disease activity and medications were included as covariates in multivariable logistic regression models. Analyses were further stratified according to rheumatic disease category. Results Of 3729 patients (mean age 57 years, 68% female), 390 (10.5%) died. Independent factors associated with COVID-19-related death were age (66-75 years: OR 3.00, 95% CI 2.13 to 4.22; >75 years: 6.18, 4.47 to 8.53; both vs ≤65 years), male sex (1.46, 1.11 to 1.91), hypertension combined with cardiovascular disease (1.89, 1.31 to 2.73), chronic lung disease (1.68, 1.26 to 2.25) and prednisolone-equivalent dosage >10 mg/day (1.69, 1.18 to 2.41; vs no glucocorticoid intake). Moderate/high disease activity (vs remission/low disease activity) was associated with higher odds of death (1.87, 1.27 to 2.77). Rituximab (4.04, 2.32 to 7.03), sulfasalazine (3.60, 1.66 to 7.78), immunosuppressants (azathioprine, cyclophosphamide, ciclosporin, mycophenolate or tacrolimus: 2.22, 1.43 to 3.46) and not receiving any disease-modifying anti-rheumatic drug (DMARD) (2.11, 1.48 to 3.01) were associated with higher odds of death, compared with methotrexate monotherapy. Other synthetic/biological DMARDs were not associated with COVID-19-related death. Conclusion Among people with rheumatic disease, COVID-19-related death was associated with known general factors (older age, male sex and specific comorbidities) and disease-specific factors (disease activity and specific medications). The association with moderate/high disease activity highlights the importance of adequate disease control with DMARDs, preferably without increasing glucocorticoid dos

Published
2021

63. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry

Author

Sparks, J, Wallace, Z, Seet, A, Gianfrancesco, M, Izadi, Z, Hyrich, K, Strangfeld, A, Gossec, L, Carmona, L, Mateus, E, Lawson-Tovey, S, Trupin, L, Rush, S, Katz, P, Schmajuk, G, Jacobsohn, L, Wise, L, Gilbert, E, Duarte-Garcia, A, Valenzuela-Almada, M, Pons-Estel, G, Isnardi, C, Berbotto, G, Hsu, T, D'Silva, K, Patel, N, Kearsley-Fleet, L, Schafer, M, Ribeiro, S, Al Emadi, S, Tidblad, L, Scire, C, Raffeiner, B, Thomas, T, Flipo, R, Avouac, J, Seror, R, Bernardes, M, Cunha, M, Hasseli, R, Schulze-Koops, H, Muller-Ladner, U, Specker, C, De Souza, V, Da Mota, L, Gomides, A, Dieude, P, Nikiphorou, E, Kronzer, V, Singh, N, Ugarte-Gil, M, Wallace, B, Akpabio, A, Thomas, R, Bhana, S, Costello, W, Grainger, R, Hausmann, J, Liew, J, Sirotich, E, Sufka, P, Robinson, P, Machado, P, Yazdany, J, Sparks J. A., Wallace Z. S., Seet A. M., Gianfrancesco M. A., Izadi Z., Hyrich K. L., Strangfeld A., Gossec L., Carmona L., Mateus E. F., Lawson-Tovey S., Trupin L., Rush S., Katz P., Schmajuk G., Jacobsohn L., Wise L., Gilbert E. L., Duarte-Garcia A., Valenzuela-Almada M. O., Pons-Estel G. J., Isnardi C. A., Berbotto G. A., Hsu T. Y. -T., D'Silva K. M., Patel N. J., Kearsley-Fleet L., Schafer M., Ribeiro S. L. E., Al Emadi S., Tidblad L., Scire C. A., Raffeiner B., Thomas T., Flipo R. -M., Avouac J., Seror R., Bernardes M., Cunha M. M., Hasseli R., Schulze-Koops H., Muller-Ladner U., Specker C., De Souza V. A., Da Mota L. M. H., Gomides A. P. M., Dieude P., Nikiphorou E., Kronzer V. L., Singh N., Ugarte-Gil M. F., Wallace B., Akpabio A., Thomas R., Bhana S., Costello W., Grainger R., Hausmann J. S., Liew J. W., Sirotich E., Sufka P., Robinson P. C., MacHado P. M., Yazdany J., Sparks, J, Wallace, Z, Seet, A, Gianfrancesco, M, Izadi, Z, Hyrich, K, Strangfeld, A, Gossec, L, Carmona, L, Mateus, E, Lawson-Tovey, S, Trupin, L, Rush, S, Katz, P, Schmajuk, G, Jacobsohn, L, Wise, L, Gilbert, E, Duarte-Garcia, A, Valenzuela-Almada, M, Pons-Estel, G, Isnardi, C, Berbotto, G, Hsu, T, D'Silva, K, Patel, N, Kearsley-Fleet, L, Schafer, M, Ribeiro, S, Al Emadi, S, Tidblad, L, Scire, C, Raffeiner, B, Thomas, T, Flipo, R, Avouac, J, Seror, R, Bernardes, M, Cunha, M, Hasseli, R, Schulze-Koops, H, Muller-Ladner, U, Specker, C, De Souza, V, Da Mota, L, Gomides, A, Dieude, P, Nikiphorou, E, Kronzer, V, Singh, N, Ugarte-Gil, M, Wallace, B, Akpabio, A, Thomas, R, Bhana, S, Costello, W, Grainger, R, Hausmann, J, Liew, J, Sirotich, E, Sufka, P, Robinson, P, Machado, P, Yazdany, J, Sparks J. A., Wallace Z. S., Seet A. M., Gianfrancesco M. A., Izadi Z., Hyrich K. L., Strangfeld A., Gossec L., Carmona L., Mateus E. F., Lawson-Tovey S., Trupin L., Rush S., Katz P., Schmajuk G., Jacobsohn L., Wise L., Gilbert E. L., Duarte-Garcia A., Valenzuela-Almada M. O., Pons-Estel G. J., Isnardi C. A., Berbotto G. A., Hsu T. Y. -T., D'Silva K. M., Patel N. J., Kearsley-Fleet L., Schafer M., Ribeiro S. L. E., Al Emadi S., Tidblad L., Scire C. A., Raffeiner B., Thomas T., Flipo R. -M., Avouac J., Seror R., Bernardes M., Cunha M. M., Hasseli R., Schulze-Koops H., Muller-Ladner U., Specker C., De Souza V. A., Da Mota L. M. H., Gomides A. P. M., Dieude P., Nikiphorou E., Kronzer V. L., Singh N., Ugarte-Gil M. F., Wallace B., Akpabio A., Thomas R., Bhana S., Costello W., Grainger R., Hausmann J. S., Liew J. W., Sirotich E., Sufka P., Robinson P. C., MacHado P. M., and Yazdany J.

Abstract

Objective To investigate baseline use of biologic or targeted synthetic (b/ts) disease-modifying antirheumatic drugs (DMARDs) and COVID-19 outcomes in rheumatoid arthritis (RA). Methods We analysed the COVID-19 Global Rheumatology Alliance physician registry (from 24 March 2020 to 12 April 2021). We investigated b/tsDMARD use for RA at the clinical onset of COVID-19 (baseline): abatacept (ABA), rituximab (RTX), Janus kinase inhibitors (JAKi), interleukin 6 inhibitors (IL-6i) or tumour necrosis factor inhibitors (TNFi, reference group). The ordinal COVID-19 severity outcome was (1) no hospitalisation, (2) hospitalisation without oxygen, (3) hospitalisation with oxygen/ventilation or (4) death. We used ordinal logistic regression to estimate the OR (odds of being one level higher on the ordinal outcome) for each drug class compared with TNFi, adjusting for potential baseline confounders. Results Of 2869 people with RA (mean age 56.7 years, 80.8% female) on b/tsDMARD at the onset of COVID-19, there were 237 on ABA, 364 on RTX, 317 on IL-6i, 563 on JAKi and 1388 on TNFi. Overall, 613 (21%) were hospitalised and 157 (5.5%) died. RTX (OR 4.15, 95% CI 3.16 to 5.44) and JAKi (OR 2.06, 95% CI 1.60 to 2.65) were each associated with worse COVID-19 severity compared with TNFi. There were no associations between ABA or IL6i and COVID-19 severity. Conclusions People with RA treated with RTX or JAKi had worse COVID-19 severity than those on TNFi. The strong association of RTX and JAKi use with poor COVID-19 outcomes highlights prioritisation of risk mitigation strategies for these people.

Published
2021

64. An Assessment in SpondyloArthritis International Society (ASAS)-endorsed definition of clinically important worsening in axial spondyloarthritis based on ASDAS

Author

Molto, Anna, Gossec, Laure, Meghnathi, Bhowmik, Landewé, Robert B M, van der Heijde, Désirée, Atagunduz, Pamir, Elzorkany, Bassel Kamal, Akkoc, Nurullah, Kiltz, Uta, Gu, Jieruo, Wei, James Cheng Chung, Dougados, Maxime, Molto, A, Gossec, L, Meghnathi, B, RLANDEWE, Der heijde, D Van, Atagunduz, P, Zorkany, B El, Akkoc, N, Kiltz, U, Gu, J, Wei, J Cheng-chung, Pandya, M Dougados,s, Navarro, V, Gaydukova, I, Geher, P, Spoorenberg, A, Aydin, S, Pimentel, F, Kishimoto, M, Gallen, F Van, Collantes-estevez, E, Schiotis, R, Marzo-ortega, H, O’shea, B, Ramos-remus, C, and Magrey, And M

Published
2018
Full Text
View/download PDF

65. EULAR/eumusc.net standards of care for rheumatoid arthritis: cross-sectional analyses of importance, level of implementation and care gaps experienced by patients and rheumatologists across 35 European countries

Author

Meisters, R, Putrik, P, Ramiro, S, Hifinger, M, Keszei, A, Van Eijk-Hustings, Y, Woolf, A, Smolen, J, Stamm, T, Stoffer-Marx, M, Uhlig, T, Moe, R, De Wit, M, Tafaj, A, Mukuchyan, V, Studenic, P, Verschueren, P, Shumnalieva, R, Charalambous, P, Vencovsky, J, Varvouni, M, Kull, M, Puolakka, K, Gossec, L, Gobejishvili, N, Detert, J, Sidiropoulos, P, Pentek, M, Kane, D, Scire, C, Arad, U, Andersone, D, Van De Laar, M, Van Der Helm-Van Mil, A, Gluszko, P, Cunha-Miranda, L, Berghea, F, Damjanov, N, Tomsic, M, Carmona, L, Turesson, C, Ciurea, A, Shukurova, S, Inanc, N, Verstappen, S, Boonen, A, Meisters R., Putrik P., Ramiro S., Hifinger M., Keszei A. P., Van Eijk-Hustings Y., Woolf A. D., Smolen J. S., Stamm T. A., Stoffer-Marx M., Uhlig T., Moe R. H., De Wit M., Tafaj A., Mukuchyan V., Studenic P., Verschueren P., Shumnalieva R., Charalambous P., Vencovsky J., Varvouni M., Kull M., Puolakka K., Gossec L., Gobejishvili N., Detert J., Sidiropoulos P., Pentek M., Kane D., Scire C. A., Arad U., Andersone D., Van De Laar M., Van Der Helm-Van Mil A., Gluszko P., Cunha-Miranda L., Berghea F., Damjanov N. S., Tomsic M., Carmona L., Turesson C., Ciurea A., Shukurova S., Inanc N., Verstappen S. M. M., Boonen A., Meisters, R, Putrik, P, Ramiro, S, Hifinger, M, Keszei, A, Van Eijk-Hustings, Y, Woolf, A, Smolen, J, Stamm, T, Stoffer-Marx, M, Uhlig, T, Moe, R, De Wit, M, Tafaj, A, Mukuchyan, V, Studenic, P, Verschueren, P, Shumnalieva, R, Charalambous, P, Vencovsky, J, Varvouni, M, Kull, M, Puolakka, K, Gossec, L, Gobejishvili, N, Detert, J, Sidiropoulos, P, Pentek, M, Kane, D, Scire, C, Arad, U, Andersone, D, Van De Laar, M, Van Der Helm-Van Mil, A, Gluszko, P, Cunha-Miranda, L, Berghea, F, Damjanov, N, Tomsic, M, Carmona, L, Turesson, C, Ciurea, A, Shukurova, S, Inanc, N, Verstappen, S, Boonen, A, Meisters R., Putrik P., Ramiro S., Hifinger M., Keszei A. P., Van Eijk-Hustings Y., Woolf A. D., Smolen J. S., Stamm T. A., Stoffer-Marx M., Uhlig T., Moe R. H., De Wit M., Tafaj A., Mukuchyan V., Studenic P., Verschueren P., Shumnalieva R., Charalambous P., Vencovsky J., Varvouni M., Kull M., Puolakka K., Gossec L., Gobejishvili N., Detert J., Sidiropoulos P., Pentek M., Kane D., Scire C. A., Arad U., Andersone D., Van De Laar M., Van Der Helm-Van Mil A., Gluszko P., Cunha-Miranda L., Berghea F., Damjanov N. S., Tomsic M., Carmona L., Turesson C., Ciurea A., Shukurova S., Inanc N., Verstappen S. M. M., and Boonen A.

Abstract

Objective As part of European League against Rheumatism (EULAR)/European Musculoskeletal Conditions Surveillance and Information Network, 20 user-focused standards of care (SoCs) for rheumatoid arthritis (RA) addressing 16 domains of care were developed. This study aimed to explore gaps in implementation of these SoCs across Europe. Methods Two cross-sectional surveys on the importance, level of and barriers (patients only) to implementation of each SoC (0-10, 10 highest) were designed to be conducted among patients and rheumatologists in 50 European countries. Care gaps were calculated as the difference between the actual and maximum possible score for implementation (ie, 10) multiplied by the care importance score, resulting in care gaps (0-100, maximal gap). Factors associated with the problematic care gaps (ie, gap≥30 and importance≥6 and implementation<6) and strong barriers (≥6) were further analysed in multilevel logistic regression models. Results Overall, 26 and 31 countries provided data from 1873 patients and 1131 rheumatologists, respectively. 19 out of 20 SoCs were problematic from the perspectives of more than 20% of patients, while this was true for only 10 SoCs for rheumatologists. Rheumatologists in countries with lower gross domestic product and non-European Union countries were more likely to report problematic gaps in 15 of 20 SoCs, while virtually no differences were observed among patients. Lack of relevance of some SoCs (71%) and limited time of professionals (66%) were the most frequent implementation barriers identified by patients. Conclusions Many problematic gaps were reported across several essential aspects of RA care. More efforts need to be devoted to implementation of EULAR SoCs.

Published
2020

66. Secukinumab Provides Sustained Reduction in Fatigue in Patients with Ankylosing Spondylitis: Long‐term Results of Two Phase III Randomized Controlled Trials

Author

Kvien, TK, Conaghan, PG, Gossec, L, Strand, V, Østergaard, M, Poddubnyy, D, Williams, N, Porter, B, Shete, A, Gilloteau, I, and Deodhar, A

Abstract

Objective To investigate the longer‐term effects of secukinumab 150 mg on fatigue in patients with ankylosing spondylitis (AS) in MEASURE 1 (up to 3 years) and MEASURE 2 (up to 2 years). Methods Patients with active AS were randomized to secukinumab or placebo in MEASURE 1 (10 mg/kg intravenous [IV] followed by 150 mg subcutaneous [SC]) and MEASURE 2 (150 mg SC). Patients were naive to or had an inadequate response/intolerance to tumor necrosis factor inhibitors (anti‐TNF‐naive/ anti‐TNF‐IR). Fatigue was measured using the Functional Assessment of Chronic Illness Therapy‐Fatigue (FACIT‐F) scale. Relationships between fatigue response and baseline characteristics and clinical/laboratory variables were explored. Results Significant improvements in FACIT‐F scores from baseline were observed with secukinumab across both studies versus placebo at week 16 (P < 0.05). Improvements were sustained through week 156 (MEASURE 1)/week 104 (MEASURE 2). Significantly more patients reported fatigue responses (FACIT‐F increase ≥4; observed data) with secukinumab 150 mg than placebo at week 16 in both MEASURE 1 (P < 0.05) and MEASURE 2 (P < 0.01). Fatigue responses were achieved by 75.6% of patients receiving secukinumab at week 156 (MEASURE 1) and 81.4% at week 104 (MEASURE 2); these results were consistent in both anti‐TNF‐naive (74.3% and 84.6%) and anti‐TNF‐IR (81.3% and 75.0%) patients. Baseline characteristics did not predict improvement in fatigue consistently. Fatigue responses were moderately to strongly correlated with responses in several clinical measures, including Assessment of SpondyloArthritis international Society (ASAS)20/40, ASAS5/6 responses, Ankylosing Spondylitis Disease Activity Score‐C reactive protein (ASDAS‐CRP), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), and Short‐form (SF)‐36 scores. Conclusion Secukinumab provided rapid and sustained improvements in fatigue for up to 3 years, regardless of prior anti‐TNF exposure.

Published
2022

70. POS1079 CLINICAL CHARACTERIZATION OF PRODROMAL AND VERY EARLY PSORIATIC ARTHRITIS: A SYSTEMATIC LITERATURE REVIEW FOR THE DEFINITION OF CLINICAL AND IMAGING SUSPICIOUS FEATURES FOR PROGRESSION TO PSORIATIC ARTHRITIS

Author

Zabotti, A., primary, De Marco, G., additional, Gossec, L., additional, Baraliakos, X., additional, Emmel, J., additional, Aletaha, D., additional, Iagnocco, A., additional, Smolen, J. S., additional, and Mcgonagle, D., additional

Published
2022
Full Text
View/download PDF

72. OP0127 UNFAVORABLE PREGNANCY OUTCOME IS SIGNIFICANTLY ASSOCIATED WITH CORTICOSTEROID EXPOSURE DURING PREGNANCY IN WOMEN WITH RHEUMATOID ARTHRITIS: ANALYSIS OF THE PROSPECTIVE GR2 COHORT

Author

Hamroun, S., primary, Couderc, M., additional, Flipo, R. M., additional, Gossec, L., additional, Richez, C., additional, Belkhir, R., additional, Frazier-Mironer, A., additional, Devauchelle-Pensec, V., additional, Marotte, H., additional, Sellam, J., additional, Gervais, E., additional, Deroux, A., additional, Lukas, C., additional, Dernis, E., additional, Chatelus, E., additional, Costedoat-Chalumeau, N., additional, and Moltó, A., additional

Published
2022
Full Text
View/download PDF

73. OP0249 CHARACTERISTICS ASSOCIATED WITH POOR COVID-19 OUTCOMES IN PEOPLE WITH PSORIASIS AND SPONDYLOARTHRITIS: DATA FROM THE COVID-19 PsoProtect AND GLOBAL RHEUMATOLOGY ALLIANCE PHYSICIAN-REPORTED REGISTRIES

Author

Machado, P. M., primary, Schaefer, M., additional, Mahil, S., additional, Dand, N., additional, Gianfrancesco, M., additional, Lawson-Tovey, S., additional, Yiu, Z., additional, Yates, M., additional, Hyrich, K., additional, Gossec, L., additional, Carmona, L., additional, Mateus, E., additional, Wiek, D., additional, Bhana, S., additional, Gore-Massy, M., additional, Grainger, R., additional, Hausmann, J., additional, Sufka, P., additional, Sirotich, E., additional, Wallace, Z., additional, Olofsson, T., additional, Lomater, C., additional, Romeo, N., additional, Wendling, D., additional, Pham, T., additional, Miceli Richard, C., additional, Fautrel, B., additional, Silva, L., additional, Santos, H., additional, Martins, F. R., additional, Hasseli, R., additional, Pfeil, A., additional, Regierer, A., additional, Isnardi, C., additional, Soriano, E., additional, Quintana, R., additional, Omura, F., additional, Machado Ribeiro, F., additional, Pinheiro, M., additional, Bautista-Molano, W., additional, Alpizar-Rodriguez, D., additional, Saad, C., additional, Dubreuil, M., additional, Haroon, N., additional, Gensler, L. S., additional, Dau, J., additional, Jacobsohn, L., additional, Liew, J., additional, Strangfeld, A., additional, Barker, J., additional, Griffiths, C. E. M., additional, Robinson, P., additional, Yazdany, J., additional, and Smith, C., additional

Published
2022
Full Text
View/download PDF

74. AB0889 Association Between Clinically Meaningful Improvements in Patient-Reported Outcomes and Stringent Measures of Disease Activity in Patients With Psoriatic Arthritis Treated With Upadacitinib Versus Placebo or Adalimumab: Results From a Phase 3 Trial

Author

Gossec, L., primary, Damjanov, N., additional, Tsuji, S., additional, Lertratanakul, A., additional, Lippe, R., additional, Patel, J., additional, Zueger, P., additional, and De Vlam, K., additional

Published
2022
Full Text
View/download PDF

75. OP0153 PRECONCEPTIONAL NSAID TREATMENT IS ASSOCIATED WITH LONGER TIME-TO-CONCEPTION IN WOMEN WITH SPONDYLOARTHRITIS: ANALYSIS OF THE PROSPECTIVE GR2 COHORT

Author

Hamroun, S., primary, Couderc, M., additional, Flipo, R. M., additional, Sellam, J., additional, Richez, C., additional, Dernis, E., additional, Frazier-Mironer, A., additional, Gossec, L., additional, Gervais, E., additional, Marotte, H., additional, Dunogeant, L., additional, Lukas, C., additional, Deroux, A., additional, Costedoat-Chalumeau, N., additional, and Moltó, A., additional

Published
2022
Full Text
View/download PDF

76. POS1076 OBESITY IS ASSOCIATED WITH LESS LIKELIHOOD OF REMISSION/ LOW DISEASE IN PSORIATIC ARTHRITIS, A CROSS-SECTIONAL STUDY OF 414 PATIENTS

Author

Leung, Y. Y., primary, Eder, L., additional, Orbai, A. M., additional, Coates, L., additional, De Wit, M., additional, Smolen, J. S., additional, Kiltz, U., additional, Palominos, P., additional, Cañete, J. D. D., additional, Scrivo, R., additional, Balanescu, A., additional, Dernis, E., additional, Meisalu, S., additional, Soubrier, M., additional, Kalyoncu, U., additional, and Gossec, L., additional

Published
2022
Full Text
View/download PDF

77. OP0252 FACTORS ASSOCIATED WITH SEVERE COVID-19 OUTCOMES IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHY: RESULTS FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE PHYSICIAN-REPORTED REGISTRY

Author

Yeoh, S. A., primary, Gianfrancesco, M., additional, Lawson-Tovey, S., additional, Hyrich, K., additional, Strangfeld, A., additional, Gossec, L., additional, Carmona, L., additional, Mateus, E., additional, Schaefer, M., additional, Richez, C., additional, Hachulla, E., additional, Holmqvist, M., additional, Scirè, C. A., additional, Hasseli, R., additional, Jayatilleke, A., additional, Hsu, T., additional, D’Silva, K., additional, Pimentel-Quiroz, V., additional, Vasquez del Mercado, M., additional, Katsuyuki Shinjo, S., additional, Reis Neto, E., additional, Rocha, L., additional, Montandon, A. C. D. O. E. S., additional, Jordan, P., additional, Sirotich, E., additional, Hausmann, J., additional, Liew, J., additional, Jacobsohn, L., additional, Gore-Massy, M., additional, Sufka, P., additional, Grainger, R., additional, Bhana, S., additional, Wallace, Z., additional, Robinson, P., additional, Yazdany, J., additional, and Machado, P., additional

Published
2022
Full Text
View/download PDF

80. POS1000 MORE THAN 30 % OF WOMEN WITH SPONDYLOARTHRITIS HAVE AN UNFAVORABLE PREGNANCY OUTCOME MOST FREQUENTLY DUE TO SMALL FOR GESTATIONAL AGE: ANALYSIS OF THE PROSPECTIVE GR2 COHORT

Author

Hamroun, S., primary, Couderc, M., additional, Flipo, R. M., additional, Sellam, J., additional, Richez, C., additional, Belkhir, R., additional, Gossec, L., additional, Marotte, H., additional, Dernis, E., additional, Frazier-Mironer, A., additional, Gervais, E., additional, Lukas, C., additional, Devauchelle-Pensec, V., additional, Dunogeant, L., additional, Deroux, A., additional, Costedoat-Chalumeau, N., additional, and Moltó, A., additional

Published
2022
Full Text
View/download PDF

81. OP0255 BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND AN INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITORS: 16-WEEK EFFICACY & SAFETY FROM BE COMPLETE, A PHASE 3, MULTICENTRE, RANDOMISED PLACEBO-CONTROLLED STUDY

Author

Merola, J. F., primary, McInnes, I., additional, Ritchlin, C. T., additional, Mease, P. J., additional, Landewé, R. B. M., additional, Asahina, A., additional, Tanaka, Y., additional, Warren, R. B., additional, Gossec, L., additional, Gladman, D. D., additional, Behrens, F., additional, Ink, B., additional, Assudani, D., additional, Bajracharya, R., additional, Coarse, J., additional, and Coates, L., additional

Published
2022
Full Text
View/download PDF

83. POS0621 MORE THAN 40% OF WOMEN WITH RHEUMATOID ARTHRITIS HAVE A TIME-TO-CONCEPTION LONGER THAN 1 YEAR: ANALYSIS OF THE PROSPECTIVE GR2 COHORT

Author

Hamroun, S., primary, Couderc, M., additional, Gossec, L., additional, Flipo, R. M., additional, Marotte, H., additional, Richez, C., additional, Frazier-Mironer, A., additional, Sellam, J., additional, Gervais, E., additional, Devauchelle-Pensec, V., additional, Deroux, A., additional, Belkhir, R., additional, Dellal, A., additional, Dunogeant, L., additional, Lukas, C., additional, Chatelus, E., additional, Costedoat-Chalumeau, N., additional, and Moltó, A., additional

Published
2022
Full Text
View/download PDF

84. LB0001 BIMEKIZUMAB IN BDMARD-NAIVE PATIENTS WITH PSORIATIC ARTHRITIS: 24-WEEK EFFICACY & SAFETY FROM BE OPTIMAL, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO-CONTROLLED, ACTIVE REFERENCE STUDY

Author

Mcinnes, I., primary, Coates, L., additional, Landewé, R. B. M., additional, Mease, P. J., additional, Ritchlin, C. T., additional, Tanaka, Y., additional, Asahina, A., additional, Gossec, L., additional, Gottlieb, A. B., additional, Warren, R. B., additional, Ink, B., additional, Assudani, D., additional, Coarse, J., additional, Bajracharya, R., additional, and Merola, J. F., additional

Published
2022
Full Text
View/download PDF

85. POS0004 WHAT DOES WORSENING IN DAPSA DISEASE ACTIVITY CATEGORIES MEAN FOR PATIENTS WITH PSORIATIC ARTHRITIS? AN ANALYSIS OF 222 PATIENTS

Author

Sousa, M., primary, Smolen, J. S., additional, Gorlier, C., additional, de Wit, M., additional, Coates, L., additional, Kalyoncu, U., additional, Ruyssen-Witrand, A., additional, Leung, K., additional, Scrivo, R., additional, Cañete, J. d. D., additional, Palominos, P., additional, Meisalu, S., additional, Balanescu, A., additional, Kiltz, U., additional, Aydin, S., additional, Gaydukova, I., additional, Dernis, E., additional, Fautrel, B., additional, Orbai, A. M., additional, Lubrano, E., additional, and Gossec, L., additional

Published
2022
Full Text
View/download PDF

86. POS1212 SARS-CoV-2 VACCINE SAFETY IN ADOLESCENTS WITH INFLAMMATORY RHEUMATIC AND MUSCULOSKELETAL DISEASES AND ADULTS WITH JUVENILE IDIOPATHIC ARTHRITIS

Author

Lawson-Tovey, S., primary, Strangfeld, A., additional, Mateus, E., additional, Gossec, L., additional, Carmona, L., additional, Machado, P., additional, Raffeiner, B., additional, Bulina, I., additional, Clemente, D., additional, Zepa, J., additional, Rodrigues, A. M., additional, Mariette, X., additional, and Hyrich, K., additional

Published
2022
Full Text
View/download PDF

87. Appariement probabiliste au système national des données de santé (SNDS) d'une cohorte de patients ayant des symptômes évocateurs d'une spondyloarthrite axiale récente, la cohorte DESIR

Author

Ajrouche, A., primary, Estellat, C., additional, Lopez-Medina, C., additional, Molto, A., additional, Ruyssen-Witrand, A., additional, Claudepierre, P., additional, De Rycke, Y., additional, Tubach, F., additional, Gossec, L., additional, and Dougados, M., additional

Published
2022
Full Text
View/download PDF

90. The role of pain and functional impairment in the decision to recommend total joint replacement in hip and knee osteoarthritis: an international cross-sectional study of 1909 patients. Report of the OARSI-OMERACT Task Force on total joint replacement

Author

Gossec, L., Paternotte, S., Maillefert, J.F., Combescure, C., Conaghan, P.G., Davis, A.M., Gunther, K.-P., Hawker, G., Hochberg, M., Katz, J.N., Kloppenburg, M., Lim, K., Lohmander, L.S., Mahomed, N.N., March, L., Pavelka, K., Punzi, L., Roos, E.M., Sanchez-Riera, L., Singh, J.A., Suarez-Almazor, M.E., and Dougados, M.

Published
2011
Full Text
View/download PDF

92. Améliorations de l’impact rapporté par les patients du rhumatisme psoriasique sous IL-12/23 (ustékinumab) et sous anti-TNF : données à un an de l’étude PsABio en vie réelle

Author

Gossec, L., primary, Siebert, S., additional, Bergmans, P., additional, De Vlam, K., additional, Gremese, E., additional, Joven-Ibanez, B., additional, Korotaeva, T., additional, Noel, W., additional, Nurmohamed, M.T., additional, Sfikakis, P.P., additional, Theander, E., additional, and Smolen, J.S., additional

Published
2021
Full Text
View/download PDF

93. Plus de 40 % des femmes atteintes de PR présentent un délai de conception supérieur à 1 an : analyse de la cohorte prospective GR2

Author

Hamroun, S., primary, Couderc, M., additional, Gossec, L., additional, Flipo, R.M., additional, Marotte, H., additional, Richez, C., additional, Frazier-Mironer, A., additional, Sellam, J., additional, Gervais, E., additional, Devauchelle Pensec, V., additional, Alban, D., additional, Belkhir, R., additional, Dellal, A., additional, Dunogeant, L., additional, Lukas, C., additional, Chatelus, E., additional, Costedoat-Chalumeau, N., additional, and Molto, A., additional

Published
2021
Full Text
View/download PDF

94. Le traitement par AINS en préconceptionnel est significativement associé à un allongement du délai conceptionnel chez les femmes atteintes de spondyloarthrite : analyse de la cohorte prospective GR2

Author

Hamroun, S., primary, Couderc, M., additional, Flipo, R.M., additional, Sellam, J., additional, Richez, C., additional, Dernis, E., additional, Frazier-Mironer, A., additional, Gossec, L., additional, Gervais, E., additional, Marotte, H., additional, Dunogeant, L., additional, Lukas, C., additional, Alban, D., additional, Costedoat-Chalumeau, N., additional, and Molto, A., additional

Published
2021
Full Text
View/download PDF

97. L’impact du rhumatisme psoriasique est plus important et la durée de maintien du traitement plus courte chez les femmes que chez les hommes traités par ustékinumab et par anti-TNF : données à un an de l’étude PsABio

Author

Gossec, L., primary, Van Der Horst-Bruinsma, I., additional, Nurmohamed, M.T., additional, Van Kuijk, A.W., additional, Siebert, S., additional, Bergmans, P., additional, De Vlam, K., additional, Gremese, E., additional, Joven-Ibanez, B., additional, Korotaeva, T., additional, Noel, W., additional, Sfikakis, P.P., additional, Theander, E., additional, and Smolen, J.S., additional

Published
2021
Full Text
View/download PDF

98. Efficacité d’upadacitinib chez des patients atteints de rhumatisme psoriasique actif ayant un nombre d’articulations gonflées élevé ou faible : analyse de sous-groupes de 2 études de phase 3 (SELECT-PsA 1 et SELECT-PsA 2)

Author

Gossec, L., primary, Gladman, D., additional, McDearmon-Blondell, E., additional, Sewerin, P., additional, Ritchlin, C., additional, Feng, D., additional, Lertratanakul, A., additional, Ranza, R., additional, Tam, L.S., additional, Marchesoni, A., additional, Coates, L., additional, and Nash, P., additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results